Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
Retrieved on:
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert
“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
Key Points:
- “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
- “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
- “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
- To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .